ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
Genomic analysis showed patients with PD on treatment had more deleterious HLA-A gene mutations in baseline samples than those with clinical activity (PR + SD).
Baseline tumor mutational burden (TMB) was comparable in baseline samples from patients with different treatment responses, but prominently increased in week 4 biopsies of PD patients – 42% mean increase for PD; 45% decrease for clinical activity.
Genomic analysis showed patients with PD on treatment had more deleterious HLA-A gene mutations in baseline samples than those with clinical activity (PR + SD).
Baseline tumor mutational burden (TMB) was comparable in baseline samples from patients with different treatment responses, but prominently increased in week 4 biopsies of PD patients – 42% mean increase for PD; 45% decrease for clinical activity.
Genomic analysis showed patients with PD on treatment had more deleterious HLA-A gene mutations in baseline samples than those with clinical activity (PR + SD).
Baseline tumor mutational burden (TMB) was comparable in baseline samples from patients with different treatment responses, but prominently increased in week 4 biopsies of PD patients – 42% mean increase for PD; 45% decrease for clinical activity.
Genomic analysis showed patients with PD on treatment had more deleterious HLA-A gene mutations in baseline samples than those with clinical activity (PR + SD).
Baseline tumor mutational burden (TMB) was comparable in baseline samples from patients with different treatment responses, but prominently increased in week 4 biopsies of PD patients – 42% mean increase for PD; 45% decrease for clinical activity.
